Development of a dynamic Parkinson's Disease database with user interface tools as a basis for internal and regulatory decision making Jackson Burton¹, Nash Delcamp², Kyle Barrett³, Steve Hummel², Seth Green³, Jingxian (JC) Chen¹, Zengtao Wang¹, Minhua Yang¹, Warren D. Hirst¹, Tien Dam⁴


¹Biogen, Inc., Cambridge, MA, USA; ²Cognigen division of Simulations Plus, Inc., CA, USA; ³Metrum Research Group, Tariffville, CT, USA ⁴Neumora Therapeutics, Inc., Watertown, MA, USA



- Parkinson's Disease (PD) drug development faces challenges around heterogeneity in disease progression, lack of validated biomarkers, and impact of symptomatic PD medications that mask drug effects.
- The composite endpoint Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been used for efficacy studies, but both sponsors and regulators face challenges in the most optimal subset of the scale to define meaningful change in disease course
- The Critical Path for Parkinson's consortium is a publicprivate partnership that works to integrate data

1) Key Data Selection:
Define underlying population and associated measures by selecting from available
studies (as singletons or combined subsets) as well
as clinical endpoints,
biomarkers, and timevarying medication use.

RESULTS – USER INTERFACE




precompetitive to help facilitate solutions for PD endpoint design among, among other efforts.



• The objective of this work is to integrate multiple PD clinical studies, harmonize the data, and deploy a user interface for rapid data interrogation and analysis subset generation.

METHODS

- Multiple PD clinical datasets were obtained from the Critical Path for Parkinson's Consortium (ref 1) and Biogen internal PD studies, including randomized clinical trials (RCTs) and observational PD studies
- Datasets were standardized to CDISC SDTM and integrated into analysis domains for demographic, biomarker, and endpoint data.
- A SQLite database was developed and used as the input into a web-based dynamic user interface (UI) developed using Shiny (R package for developing web applications) for data interrogation.
- The Shiny UI was developed to give versatile and simple to use tools for broad audiences within a clinical development team, with additional functionality for analysis subsets to be efficiently generated



2) Baseline Feature Visualization: Visualize the distribution of all available baseline variables in databased defined by key data selection. Users have the option to filter by variables and interest and save filters to examine various subpopulations. Missing data is clearly reported to give accurate representations of data completeness.

Defined subpopulations can be saved and loaded for future use. The filter criteria are also recorded to help track and compare different subpopulations.

Create Subset		
Data subset name:	Available Scenarios:	
Scenario 1	Nothing selected	<na></na>

3) Define Customized Endpoints: Users can define custom endpoints by selecting individual items from composite measures, or entire composites, and sum them. Items from individual parts MDS-UPDRS

MDS-UPDRS Sum of Scores Part 2 + 3 Totals

Plot Type

Variable

Mean Values

O Endpoint Score

Change from Baseline

O Percent Change from Baseline

4) Visualize Endpoint Trajectories:

Longitudinal trajectories can be visualized

Summary and Visualization Options					
Variable & Plot Type	Plot Stratification	Visits Included			
Endpoints to Plot		Bin Size (Months)			

State Other

Split by study

Combine across studies

Study

Methoo


RESULTS - DATABASE

 A total of 9 clinical studies (6 RCTs, 3 observational) were standardized and integrated into a SQLite database [see below]

Study	Contributor	Study Type	Reported Number subjects	Years since Dx	Duration of follow up
PPMI	MJFF	Obs	1866	de novo	Ongoing (2010)
Tracking PD	U of Glasgow	Obs	1998	de novo	3-5 years
STEADY-PD3	MJFF/U of Rochester	RCT	336	<3	3 year
SPARK	Biogen	RCT	357	<3	<2 year
BEAT-PD	Biogen	Obs	33	<5	3 years
SURE-PD3	MJFF/U of Rochester	RCT	298	<3	2 years
Azilect Ph3	Takeda	RCT	244	<5	0.5 years
Azilect Ph3 LTE	Takeda	RCT	171**	<5	1 year
PASEDENA Ph2	Roche	RCT	100	<2	1 year

Extensive data standardization based on CDISC STDM was used to generate intermediate analysis domains across the various data types including demographics, biomarkers, medication information, and clinical with options to choose duration and binned time intervals and stratify by continuous & categorical variables. For continuous variables, users can choose custom thresholds to divide the underlying population.





Duration (Months

change from baseline, and percent change from baseline


User can generate **summary statistics** of the chosen population and **view the raw data** as well.

🛓 Download Data

5) Downloadable raw data: Users can download raw data in Analysis Data Model (ADaM)-like structure. This features helps minimize additional data processing for software input. The data structure is amenable for use in NONMEM, Monolix, and Stan. Additionally, users can download a report that collects are data filter criteria, generated tables, and figures including baseline and longitudinal plots into a single report. Output options include HTML, PDF, and Word, with figures and tables embedded as standalone for eacy retrieval.



biomarkers, medication information, and clinical assessments [see below]



 A user interface (UI) was developing in Shiny using the SQLite database as input

🛃 Gen<mark>erate R</mark>eport

CONCLUSION

The developed PD dynamic database and user interface tools offers several advantages for analyzing clinical data:

- Accessibility The UI allows for audiences of diverse background to interrogate the data without the need for explicit coding
- Efficiency Real-time filtering and visualization of the data is automated, requiring little time for data analysis
- Scalability New data (likely in SDTM already) can be readily integrated into the database using the existing database structure
- **Open source** UI and underlying data structure are developed with well known, open-source tools making them easily sharable

[#]The authors recognize the Critical Path for Parkinson's consortium of the Critical Path Institute for generously sharing of the patient and item level data from the CPP Parkinson's Integrated database to support the analysis presented here.





